探索甲基替代单碳酸曲素衍生物的抗胆固醇和抗失忆潜力
Muhammad Bilal Afridi1, Syed Wadood Ali Shah2, Haya Hussain3
1Department of Pharmacy, Abdul Wali Khan University Mardan, 23200, Mardan, Pakistan.
European journal of pharmacology
|September 27, 2025
概括
新的黄素衍生物 (BL1-BL3) 在治疗阿尔茨海默病 (AD) 方面表现有前途. 这些化合物抑制关键酶并改善小鼠的记忆力,为痴呆症提供潜在的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是由于乙胆酶 (AChE) 和丁胆酶 (BChE) 活性增加,乙胆素 (ACh) 水平降低.
- 抑制ACHE和BCHE是管理AD中胆固醇功能障碍的关键策略.
研究的目的:
- 评估合成甲基替代单碳酸曲素衍生物 (BL1-BL3) 作为潜在的阿尔茨海默病治疗药物的体外和体内疗效.
- 在AD小鼠模型中研究BL1-BL3对ACHE和BCHE的抑制作用及其对认知功能和氧化应激的影响.
主要方法:
- 在体外酶抑制试验中进行了AChE和BChE的测试.
- 进行了分子对接研究,以评估结合 afinities.
- 在小鼠中使用 scopolamine 诱导失忆症,随后给予 BL1-BL3.
- 用Y迷宫和新型物体识别测试 (NORT) 评估认知功能.
- 对海马组织的生物化学分析测量了氧化应激标志物和酶水平.
主要成果:
- BL1-BL3对AChE和BChE表现出显著的抑制活性,而BL2显示出显著的有效性.
- 分子对接证实了BL1-BL3对目标酶的强烈结合亲和力.
- 用BL1-BL3进行预治疗显著缓解了小鼠的斯科波拉胺诱导的记忆缺陷,改善了自发交替性能和记忆保留.
- 治疗降低了ACHE和马隆迪阿尔海 (MDA) 水平,同时增加了海马体中的催化酶 (CAT) 和超氧化溶解酶 (SOD) 水平.
结论:
- 合成的黄素衍生物BL1-BL3显示出对阿尔茨海默病的显著治疗潜力.
- 这些化合物有效地抑制胆酶,改善认知功能,并在实验模型中减少氧化应激.
- BL2成为进一步开发抗阿尔茨海默症药物的最有前途的候选药物.
相关概念视频
Cholinergic Antagonists: Pharmacokinetics
901
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
901
Cholinergic Antagonists: Pharmacological Actions
1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K
Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K


